August 25, 2020

National Stock Exchange of India Ltd, BSE Ltd,
Exchange Plaza, 5th Floor, Market Operations Dept.
Plot No. C/1, G Block, P. J. Towers, Dalal Street,
Bandra Kurla Complex, Mumbai - 400 001.
Bandra (East), Mumbai – 400 051.
NSE Code – SUNPHARMA BSE Code – 524715

Sub:  Press Release of our subsidiary company relating to civil settlement agreements with US Department of Justice.

Dear Sirs,

Please find enclosed herewith a Press Release issued by our subsidiary company in U.S.A., Sun Pharmaceutical Industries Inc., relating to resolution of US Department of Justice (DOJ) investigation by its subsidiary company, Dusa Pharmaceuticals Inc. (Dusa).

Sun Pharmaceutical Industries Ltd. had already disclosed about an in-principle agreement (in respect of which now Dusa has interalia signed the civil settlement agreements with the DOJ) in the notes to consolidated accounts of its March-2020 quarterly financial results and had made a provision of Rs. 156.36 Crores for this settlement.

This is for your information and dissemination.

Yours faithfully,

For Sun Pharmaceutical Industries Limited,

Ashok I Bhuta
Compliance Officer

Encl: As above
FOR IMMEDIATE RELEASE

DUSA Resolves Investigation Related to Promotion of Actinic Keratosis Drug

Princeton, NJ, August 24, 2020: DUSA Pharmaceuticals, Inc., (“DUSA”), a wholly owned subsidiary of Sun Pharmaceutical Industries, Inc. (“SPII”) today announced that it has reached a resolution with the United States Department of Justice (DOJ) concerning the promotion of LEVULAN® KERASTICK® (aminolevulinic acid HCL) and BLU-U®.

DUSA fully cooperated with DOJ in its investigation of a complaint filed by a former employee in September 2016.

Under the civil settlement agreements signed with the DOJ, DUSA will pay US$20.75 million to resolve allegations related to the promotion of LEVULAN® KERASTICK® and BLU-U®. DUSA had already made a provision towards this in its Q4 financials for the year ended March 31, 2020. The settlement does not constitute any admission by DUSA of any liability or wrongdoing.

As part of the resolution, DUSA and SPII have entered into a corporate integrity agreement with the Office of Inspector General of the U.S. Department of Health and Human Services. This agreement supplements SPII's existing compliance program, which is based upon established best practices and industry standards as well as the company's global code of conduct, which can be found here. Under the settlement agreement, the DOJ has agreed not to bring any action seeking to exclude DUSA or SPII from participating in Federal health care programs.

In a separate agreement, DUSA also fully resolved all allegations made by the former employee.

Disclaimer:
Statements in this “Document” describing the Company’s objectives, projections, estimates, expectations, plans or predictions or industry conditions or events may be “forward looking statements” within the meaning of applicable securities laws and regulations. Actual results, performance or achievements could differ materially from those expressed or implied. The Company undertakes no obligation to update or revise forward looking statements to reflect developments or circumstances that arise or to reflect the occurrence of unanticipated developments/circumstances after the date hereof.

About Sun Pharmaceuticals Industries Inc., (SPII):

Sun Pharmaceutical Industries Inc., (SPII) is a subsidiary of Sun Pharmaceutical Industries Ltd, the world's fourth largest specialty generic pharmaceutical company and India's top pharmaceutical company. A vertically integrated business and a skilled team enables it to deliver high-quality products, trusted by customers and patients in over 100 countries across the world, at affordable prices. Its global presence is supported by manufacturing facilities spread across 6 continents and approved by multiple regulatory agencies, coupled with a multi-cultural workforce comprising over 50 nationalities. Sun Pharma fosters excellence through innovation supported by strong R&D capabilities across multiple R&D centers, with investments of approximately 6% of annual revenues in R&D. For further information, please visit www.sunpharma.com.
Contacts:

U.S. Media:
Vinita Alexander
Tel Direct +1 609-720-8197
Mobile +1 732-258-6725
E mail vinita.alexander@sunpharma.com